Our Company

Company Name
Organ Technologies Inc.
Date of Incorporation
April 21, 2008
Executive Board
Yasuhiro Sugimura
Takashi Tsuji
Kenji Hanazawa
Naokazu Okamoto
Outside Director
Hironori Iwatani
Business Concept
To catalyze the regenerative medicine industry in Japan through world-first organ regeneration technologies.
Major business areas
  • ・Manufacture, sale, and import/export of medical products and materials for use in regenerative medicine
  • ・Manufacture, sale, and import/export of cells, tissues, and organs for therapeutic use (via contractors)
  • ・Manufacture, sale, import/export, leasing, and maintenance of equipment/devices for medical, industrial, and household use.
  • ・R&D and technology transfer in transplant and regenerative medicine
  • ・R&D and scientific tests related to medical care
A Certified RIKEN Venture Company


April 2008 Organ Technologies Inc. founded with investment from Otsuka Chemical Co. Ltd.
June 2008 Joint research on next-generation organ regeneration technologies started in partnership with Tokyo University of Science
February 2010 Patent published on orthotopic teeth regeneration using the organ germ method
August 2010 Patent published on methods to control the size and shape of regrown teeth
August 2011 Patent published on ex vivo organ perfusion culture system
October 2011 Patent published on transplantation of regrown tooth units
Patent published on a restoration method for alveolar bone
February 2012 Major research site for Organ Technologies established at Tokyo University of Science, which begins activities
August 2012 Patent published on a transplantation method for regrown hair
Patent published on a method to control hair color
April 2013 Organ Technologies becomes independent through share buyback from Otsuka Chemical
April 2014 Director Takashi Tsuji, PhD (Organ Technologies) appointed Group Director of the RIKEN Laboratory for Organ Regeneration
April 2015 Journal paper published in Scientific Reports (“Hypothermic temperature effects on organ survival and restoration”)
December 2015 RIKEN Integrated Innovation Building (IIB) opens its doors
December 2015 Journal paper published in Scientific Reports (“Functional tooth restoration utilizing split germs through re-regionalization of the tooth-forming field”)
April 2016 Journal paper published in Science Advances (“Bioengineering a 3D integumentary organ system from iPS cells using an in vivo transplantation model”)
May 2017 Certified as a RIKEN Venture company
December 2017 Coalition of 18 member organizations, “The Hair Consortium” including RIKEN, Yahoo!Japan, and Aderans, began activities.
April 2018 Advanced Skin® wins Excellence Award at Small and Medium Enterprise Awards for Outstanding New Technologies and Products
June 2018 Announced the beginning of non-clinical testing of our hair follicle regeneration medicine
June 2018 Organ Technologies has issued new shares to Iyogin Capial Company Limited, ITOCHU Corporation and Mitsui & Co., Ltd..
October 2018 Received approval to manufacture and sell a Class 1 medical device from Tokyo metropolitan government.
November 2018 Hair follicle regeneration was featured in Highlighting Japan (a PR magazine published by Japan’s Cabinet Office)
January 2019 Hair Diagnostic Consortium’s efforts featured in We Are Tomodachi (an international public relations magazine published by the Japanese government)


Next-generation regenerative medicine: a benefit for public health and welfare, a driver of the next industrial revolution starting from Japan.

Organ Technologies was founded to spark a new industrial revolution starting from Japan which is one of the health care’s hottest growth fields: regenerative medicine. Our mission is to promote the health and welfare of people all over the world through our novel bioengineering technologies designed to produce realistic organs that are functionally equivalent to natural ones.

Regenerative medicine refers to a number of treatments based on cells and tissues of human origin, designed for patients ill-served by conventional ones. Organ replacement regeneration is an eagerly anticipated paradigm in the field, i.e., replacing entire organs no longer functioning due to disease or injury with new ones artificially grown outside the body. Along with Dr. Takashi Tsuji, PhD of RIKEN, we developed the “organ germ method,” a world-first technique to reconstitute organ germ tissue by manipulating cells, using biological systems for organ regeneration and engineering technology. Our goal is to utilize these technologies to meet the needs of many patients who have placed their hopes in regenerative medicine and organ transplantation.

Japan’s role in the global order has once again been called into question by changes in the structures of society and industry due to globalization. Our continued scientific and technical research is done in the hopes of not only building a clear future for Japan in the 21st century, but also making international contributions to human happiness everywhere, and creating technologies that can be handed down to later generations. To realize our vision, we believe it is the responsibility of the current generation to catalyze a new “industrial revolution” starting from Japan in the field of medicine. Regenerative medicine remains primarily the domain of small research teams, who painstakingly create single or small batches of products on a small scale. We believe this “craft production” approach lacks enough power to spark further innovation in regenerative medicine as an industry.

Tracing back the history of the (first) Industrial Revolution, one can see that mechanization and upscaling were crucial to industrialization. Since our company’s efforts alone would be insufficient to drive the same transformation in regenerative medicine, we are actively seeking partnerships with many companies who sympathize our vision to pave the way for the regenerative medicine industry.

Our basic research in regenerative technologies and our sure progress toward clinical applications are driven by the unflinching dedication of all of us at Organ Technologies toward a common goal: to improve the health and welfare, and indeed the happiness of people everywhere.

President Yasuhiro Sugimura, August 2017

Executive Board

President - Sugimura Yasuhiro

Diploma, Rakusei Senior High School, Kyoto
B.A. Economics, Faculty of Economics, Kyoto University
Joined Morgan Stanley Securities
Joined ABN Amro Securities LLC
President and Founder, Think & Act Inc.
President, Organ Technologies Inc.

Director - Tsuji Takashi, PhD

B.S. Biology, Faculty of Science, Niigata University
M.S. Biology, Graduate School of Science, Niigata University
Research Fellow, Central Research Laboratory, Yamanouchi Pharmaceutical Co. Ltd.
Completed Ph.D. program in Biology (without degree), Graduate School of Science, Kyushu University
Research Fellow, Graduate School of Science and Technology, Niigata University
Ph.D. (Science), Niigata University
Research Fellow, Life Science Research Laboratory, Japan Tobacco Inc.
Research Fellow, Pharmaceutical Frontier Research Laboratories, Japan Tobacco Inc.
Senior Research Fellow, Pharmaceutical Frontier Research Laboratories, Japan Tobacco
Associate Professor, Department of Biological Science and Technology, Tokyo University of Science
Professor, Department of Biological Science and Technology, Tokyo University of Science
Director, Organ Technologies Inc.
Professor, Research Institute for Science & Technology, Tokyo University of Science
Master of Intellectual Property (MIP), Department of Innovation Studies, Professional Graduate School, Tokyo University of Science
Group Director, Organ Regeneration Group, RIKEN Center for Developmental Biology
Team Leader, Laboratory for Organ Regeneration, incorporated administrative agency RIKEN Center for Developmental Biology (to present)
Team Leader, Laboratory for Organ Regeneration, national research and development agency RIKEN Center for Developmental Biology (to present)
Team Leader, Laboratory for Organ Regeneration, national research and development agency RIKEN Center for Biosystems Dynamics Research (to present)

Website: Takashi Tsuji, PhD’s Lab, Laboratory for Organ Regeneration, RIKEN Center for Biosystems Dynamics Research

Director - Hanazawa Kenji

B.B.A. Accounting, School of Business Administration, Kobe University
Joined KPMG Azsa LLC
Joined PricewaterhouseCoopers Aarata LLC
Founded Hanazawa Accounting Office
Founded ASA IFRS Service Inc. (ASA Total Solution Inc.)
Director, Organ Technologies Inc.

Director - Okamoto Naokazu

B.S. Biological Science and Technology, Faculty of Industrial Science and Technology, Tokyo University of Science
M.S. Biological Science and Technology, Faculty of Industrial Science and Technology, Tokyo University of Science
Joined SRD Co., Ltd.
Joined Applied Biosystems Japan, Ltd. (now AB Sciex LLC)
Joined Organ Technologies Inc.
Director, Organ Technologies Inc.

Outside Director - Iwatani Hironori

B.A. Law, Faculty of Law, Kyoto University
J.D., Graduate School of Law, Kyoto University (Attorney Training Course)
Passed new Japanese bar exam
Joined Nishimura & Asahi
LL.M., School of Law, University of California, Berkeley
Opened Iwatani Muramoto & Yamaguchi
Licensed to practice in the State of New York (U.S.)
Outside Director, Organ Technologies Inc.


Head Office(Minato Ward, Tokyo)
Toto Building, 5F Toranomon 5-1-4 Minato-ku, Tokyo 105-0001
Joint Research Center(Kobe City, Hyogo)
RIKEN Integrated Innovation Building (IIB) Minatojima Minami-machi 6-7-1 Chuo-ku Kobe-shi, Hyogo-ken 650-0047

Research and Development Center
(Kobe City, Hyogo)
Minatojima Minami-machi 3-3-13 Chuo-ku, Kobe-shi, Hyogo-ken 650-0047
(Shinjuku Ward, Tokyo)
S.COURT #204 Shinanomachi 3-1 Sinjuku-ku, Tokyo 160-0016